Press Releases
Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc; the FDA offers Special Protocol Assesment for Reviroc
19-12-2007 Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Fo... read more
ATIR classified as “cell based” medicinal product by the EMEA; a classification for innovative new treatments
14-12-2007 Kiadis Pharma announced today that its lead product ATIR has received approval for regulatory classification as a “cell... read more
Promising data ATIR studies presented by NIH Investigators
28-11-2007 Kiadis Pharma announced today the presentation of the results obtained so far in the physician initiated study led by Dr... read more
Kiadis Pharma presents at the ISCT Global Regulatory Perspectives Workshop on 23 May in Philadelphia, USA
23-11-2007 Amsterdam, 20 May, 2010 – Biopharmaceutical company Kiadis Pharma announced today that the company’s Vice President Clin... read more
Kiadis Pharma presents ATIR and Rhitol data at ASH
23-11-2007 And NIH presentation on ATIR at ASH Oncology focused biotech company Kiadis Pharma announces today that there will be th... read more
Kiadis Pharma continues to provide Rhitol to participating physicians during completion of current clinical study
19-11-2007 Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physici... read more
FDA grants Kiadis Pharma lead product ATIR orphan drug designation
7-11-2007 Kiadis Pharma announced today that its lead product ATIR has been granted orphan drug designation by the US Food and Dru... read more
Interim Clinical Results ATIR
10-10-2007 Successful Independent Clinical Evaluation of ATIR by Dr. Velardi for Mismatched Bone Marrow Transplantation Kiadis... read more
Promising Phase II Clinical Trial Results for Reviroc
31-8-2007 Groningen, August 31, 2007 – Oncology focused pharmaceutical development company Kiadis Pharma announced today that it h... read more
Kiadis Pharma Completes Patient Enrollment of Rhitol phase I/II Clinical Trial
17-8-2007 Groningen, August 17, 2007 – Oncology focused pharmaceutical company Kiadis Pharma announced today that it has enrolled... read more
Kiadis Pharma obtains SME status from EMEA
21-7-2007 Groningen, 21 July 2007 – Oncology focused pharmaceutical product development company Kiadis Pharma announced today that... read more
Kiadis Pharma Announces Clinical Study with NIH
9-7-2007 July 9, 2007 – Oncology focused pharmaceutical company Kiadis Pharma B.V. announced today that physicians at the U.S. Na... read more
Investering van €15 Miljoen in Kiadis Pharma voor Ontwikkeling van Oncologie Medicijnen
26-6-2007 Amsterdam, June 26, 2007 – Oncology product development company Kiadis Pharma announced today that it has completed a €1... read more
First European results for Kiadis Pharma ATIR
28-3-2007 Professor Velardi has obtained pre-clinical and initial clinical data supporting ATIR as strategy for Mismatched Stem C... read more
Clinical data on ATIR presented.
12-2-2007 ATIR initial Clinical Data suggests; Feasible Strategy for Mismatched Stem Cell Transplantation Keystone, February... read more
Acquisition of Assets wnt-pathway
19-1-2007 Kiadis Pharma Acquires Assets to Develop Novel Cancer Treatments Acquisition of patents, compounds, targets, researc... read more
Kiadis Pharma Press Releases
Kiadis Pharma Press Releases are available via an RSS feed. To add this RSS feed to your reader, right click on the RSS button, click "Copy Shortcut" and add the URL to your feed reader.
